pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,354 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1032Endpoints785BioPharma Dive299BioSpace219Fierce Biotech207onclive165raps78globenewswire health
therapy area
allOncology6110Rare Disease1467Cardiology1094Hematology1031Immunology1020Vaccines919Pulmonology
  • Nancy Cox, a CDC veteran and a stalwart in global flu research, dies at 77
    Nancy Cox, a CDC veteran who for decades was a global leader in influenza research, has died at 77.
    STAT · 3mo ago↗ source
  • Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
    “We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
    STAT · 3mo ago↗ source
  • Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and more
    Welcome back to another edition of Endpoints Weekly! We’re doing a little bit of celebrating here at Endpoints, as we took home three Neal Awards, which recognize excellence in B2B journalism. The ...
    Endpoints · 3mo ago↗ source
← prev
page 93 of 95
next →
73
fda recalls48
fda medwatch41
fda press28
911
Psychiatry & CNS727
Ophthalmology425
Pain406
Endocrinology & Metabolism390
Infectious Disease362
  • STAT+: FDA to speed up review of three psychedelics as mental health treatments
    Trump's embrace of psychedelics and cannabis is shaking up the GOP’s relationship with mind-altering substances.
    STAT · 4mo ago↗ source
  • STAT+: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B
    What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts has some answers.
    STAT · 4mo ago↗ source
  • FDA unveils three psychedelic-focused commissioner vouchers
    The FDA said Friday it has issued new fast-track vouchers to three psychedelic companies, and its selections have come as a “surprise” to Wall Street. In an unusual move, the agency didn’t name the…
    Endpoints · 4mo ago↗ source
  • STAT+: Utah medical board calls for immediate suspension of state’s AI doctor experiment
    A Utah pilot to renew prescriptions using a bot faced backlash from the state's medical board, which called for an immediate suspension.
    STAT · 4mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 4mo ago↗ source
  • Sanofi MS drug rejected in US gets an endorsement in Europe
    Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions the therapy for its first regulatory approval.
    BioPharma Dive · 4mo ago↗ source
  • Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drug
    Avalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if it prices its initial public…
    Endpoints · 4mo ago↗ source
  • Novartis pulls Pluvicto prostate cancer label expansion filing in the EU
    Novartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication. The Swiss drugmaker failed to gain fav…
    Endpoints · 4mo ago↗ source
  • Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
    Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.
    BioPharma Dive · 4mo ago↗ source
  • Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy
    The new generation of weight loss medicines does an unprecedented job of keeping off the pounds — if people stay on the drugs. Yet numerous studies suggest most of those who start taking GLP-1 drug…
    Endpoints · 4mo ago↗ source
  • International childhood vaccine campaign grows
    In today's Morning Rounds newsletter, a new era in GOP drug policy, an international childhood vaccine campaign grows, and more.
    STAT · 4mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Trump deal with Regeneron, reclassifying medical marijuana, and more
    President Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White House
    STAT · 4mo ago↗ source
  • STAT+: Sanofi MS drug gets positive review in Europe following FDA
    A multiple sclerosis drug from Sanofi that was rejected late last year by the FDA found a warmer reception in Europe.
    STAT · 4mo ago↗ source
  • Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection
    Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the FDA in December. On Friday, the European Med…
    Endpoints · 4mo ago↗ source
  • Pfizer’s strategy chief Andrew Baum steps down; Helus Pharma swaps out CEO after two months
    → Ex-Citi analyst Andrew Baum has left his role as chief strategy and innovation officer at Pfizer, but he will be a senior strategic advisor to CEO Albert Bourla. BMO Capital Markets broke the new…
    Endpoints · 4mo ago↗ source
  • Daiichi Sankyo postpones annual results, stock dips
    Daiichi Sankyo has pushed back the reporting of its annual results, saying it needs more time to finalize the numbers. The Japanese company had intended to unveil its financials for its fiscal year…
    Endpoints · 4mo ago↗ source
  • Opinion: I started medical school at 69 and will begin residency at 72. Here’s what I learned
    Starting residency at 72 isn’t for the faint of heart. But that’s what Dawn Zuidegeest-Craft is doing.
    STAT · 4mo ago↗ source
  • Psychedelics get a boost from the White House
    In this week’s STATus Report, host Alex Hogan chats with STAT Washington correspondent Daniel Payne about Trump's psychedelics EO.
    STAT · 4mo ago↗ source
  • Opinion: The local news crisis is also a public health crisis
    Health and science reporting is often treated as optional coverage. It is anything but.
    STAT · 4mo ago↗ source
  • Growing use of guest editors has turned some journals into a ‘playground of bad science’
    The problematic use of guest editors was spotlighted last week when a genetics journal retracted nearly an entire special issue.
    STAT · 4mo ago↗ source
  • A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts
    This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen now.
    STAT · 4mo ago↗ source
  • STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
    A deal with Regeneron was the last of 17 initially sought by the White House.
    STAT · 4mo ago↗ source